Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride

Abstract

2-Bromolisuride (2-Br-LIS), a derivative of the ergot dopamine (DA) agonist lisuride, was investigated in rodents in comparison with the DA antagonist haloperidol with regard to its influence on DA related behaviour, cerebral DA metabolism and prolactin (PRL) secretion. 2-Br-LIS produced catalepsy in mice (ED 50 3.3 mg/kg i.p.), antagonized apomorphine-induced stereotypies in mice (ED 50 0.4 mg/kg i.p.), antagonized DA agonist-induced stereotypies in rats (0.1–1.56 mg/kg i.p.), inhibited locomotor activity in rats (0.025–6.25 mg/kg i.p.), antagonized the hyperactivity produced by various DA agonists in rats (0.025–6.25 mg/kg i.p.) and inhibited the apomorphine-induced hypothermia in mice (0.05–0.78 mg/kg i.p.). 2-Br-LIS (0.03–10 mg/kg i.p.) stimulated DA biosynthesis and DOPAC formation in the striatum and DA rich limbic system of rats, but had no effect on serotonin turnover. In striatum and limbic forebrain of γ-butyrolactone-pretreated rats 2-Br-LIS reversed the apomorphine-induced inhibition of DOPA accumulation. 2-Br-LIS (0.03 – 3 mg/kg) enhanced PRL secretion in intact male rats. These findings indicate DA antagonistic properties of 2-Br-LIS presumably due to blockade of central pre- and postsynaptic DA receptors being of approximately the same order of potency as haloperidol. 2-Br-LIS is the first ergot compound with definite antidopaminergic properties suggesting its potential usefulness as a neuroleptic.